Location preference

Enter your country so we can show you products that are available for you.

Spectra Optia Processing Protocol

Supporting patient treatment through bone marrow processing

While the Spectra Optia™ Apheresis System from Terumo Blood and Cell Technologies is often known for its role in therapeutic apheresis, the platform can also be used for collecting valuable cells from a patient’s or donor’s bone marrow. Browse the protocol details* below for more information. If you have questions, please reach out to our apheresis device and procedure experts.

 

Processing

Bone marrow processing (BMP)

Through helpful on-screen guidance and a single-bag approach, the Spectra Optia system simplifies BMP procedures.

Procedure information

  • Performs red blood cell reduction greater than 97%**
  • Provides volume reduction greater than 90%**
  • Produces a final product volume under 200 mL**
  • Requires less operator supervision, as the system continuously monitors and adjusts the interface 
  • Typical extracorporeal volume (ECV) is 141 mL; maximum ECV is 185 mL

Graphical user interface (GUI) for BMP procedures

Featured resources

See how the Spectra Optia system can be the solution to your apheresis and cell collection needs.

Explore other protocols available on Spectra Optia

Spectra Optia protocols
Exchange
Spectra Optia protocols
Collection
Spectra Optia protocols
Depletion

Contraindications

  • There are no known contraindications for the system's use, except for those associated with all automated apheresis systems.
  • The infusion of certain solutions and replacement fluids may be contraindicated in some patients.

Possible patient reactions

  • Anxiety, headache, light-headedness, digital and/or facial paresthesia, fever, chills, hematoma, hyperventilation, nausea and vomiting, syncope (fainting), urticaria, hypotension, and allergic reactions.

Reactions to transfused blood products can include1

  • Fever, circulatory overload, shock, allergic reactions, alloimmunization, graft-versus-host disease, and transmission of infection.

Restricted to prescription use only

  • Operators must be familiar with the system's operating instructions.
  • Procedures must be performed by qualified medical personnel.
  • A supervisory practitioner may supervise from a physician office or other nonhospital space that is not officially part of the hospital campus as long as he or she remains immediately available.2

Disclaimers and notes

*Product and protocol availability varies by country.

**Data on file.

Under normal operating conditions, the ECV will not exceed the typical ECV value. Under certain infrequent alarm conditions, such as during reservoir recovery after a reservoir alarm, the ECV may momentarily increase to the maximum ECV value.

1. AABB (ed.), et al., Circular of Information for the Use of Human Blood and Blood Components. 10th ed. 2006; Council of Europe Publishing, Seattle, WA.

2. American Society for Apheresis. Guidelines for documentation of therapeutic apheresis Ppocedures in the medical record by apheresis physicians. J Clin Apher. 2007; 22(3):183.

To top